ArticleBMC bioinformatics2011
Planning combinatorial disulfide cross-links for protein fold determination.
Article in BMC bioinformatics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Homology modelling of CB1 receptor and selection of potential inhibitor against Obesity.Bioinformation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFold recognition techniques take advantage of the limited number of overall structural organizations, and have become increasingly effective at identifying the fold of a given target sequence. However, in the absence of sufficient sequence identity, it remains difficult for fold recognition methods to always select the correct model. While a native-like model is often among a pool of highly ranked models, it is not necessarily the highest-ranked one, and the model rankings depend sensitively on the scoring function used. Structure elucidation methods can then be employed to decide among the models based on relatively rapid biochemical/biophysical experiments.
resultsThis paper presents an integrated computational-experimental method to determine the fold of a target protein by probing it with a set of planned disulfide cross-links. We start with predicted structural models obtained by standard fold recognition techniques. In a first stage, we characterize the fold-level differences between the models in terms of topological (contact) patterns of secondary structure elements (SSEs), and select a small set of SSE pairs that differentiate the folds. In a second stage, we determine a set of residue-level cross-links to probe the selected SSE pairs. Each stage employs an information-theoretic planning algorithm to maximize information gain while minimizing experimental complexity, along with a Bayes error plan assessment framework to characterize the probability of making a correct decision once data for the plan are collected. By focusing on overall topological differences and planning cross-linking experiments to probe them, our fold determination approach is robust to noise and uncertainty in the models (e.g., threading misalignment) and in the actual structure (e.g., flexibility). We demonstrate the effectiveness of our approach in case studies for a number of CASP targets, showing that the optimized plans have low risk of error while testing only a small portion of the quadratic number of possible cross-link candidates. Simulation studies with these plans further show that they do a very good job of selecting the correct model, according to cross-links simulated from the actual crystal structures.
conclusionsFold determination can overcome scoring limitations in purely computational fold recognition methods, while requiring less experimental effort than traditional protein structure determination approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.